Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative fluorescence imaging with OTL38 in ovarian, renal cell, and endometrial cancer
NL-OMON20365Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2014
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of pafolacianine in ovarian cancer, endometrial cancer (EC) and renal cell carcinoma (RCC), sponsored by Leiden University Medical Center. Primary endpoints: Treatment-emergent adverse events and Clinical safety assessments. Started Sep 2014; status: recruiting.
02
Drugs
pafolacianine
03
Conditions
ovarian cancerendometrial cancer (EC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON20365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20365.